Daxor Corporation
DXRHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Daxor Corporation focuses on Medical Instruments & Supplies services and products. Daxor Corporation engages in medical instrumentation and biotechnology operations. The $61.1M market capitalization puts DXR squarely in micro-cap range for its industry. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit.
Market Cap
$61.1M
Beta
0.26
P/E (TTM)
6.19
P/E (Fwd)
—
EPS (TTM)
$1.69
EPS (Fwd)
—
ROE
14.2%
ROA
-2.6%
Cash
—
Total Debt
$0
Free CF
$333,869
52W Change
-9.7%
Annual Financials
Cash vs Debt
Where DXR stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, DXR finished 0.94% above its 150-day moving average ($10.64) and 4.87% below its 200-day moving average ($11.29). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DXR overbought or oversold?
At the September 3, 2026 close, DXR's RSI(14) was 56.5, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Daxor Corporation carries $0 in total debt, a figure that investors should evaluate relative to the company's earnings power. Free cash flow comes in at $334K, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 14.2% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $5.8M (2021) to $10.3M (2025), reflecting a 77% increase over the period.
With a beta below 0.7, Daxor Corporation typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Daxor Corporation's trajectory.